You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨創新藥概念股繼續活躍,樂普生物拉昇升15%
格隆匯 07-23 11:40
港股市場創新藥概念股繼續活躍,其中,樂普生物-B(2157.HK)盤中一度拉昇升15%報8.49港元,截至目前成交近6億港元。樂普生物此前發佈公吿稱,將5426.84萬股未上市股份轉換為H股已於2025年7月21日完成,且轉換H股已於2025年7月22日開始在聯交所上市。太平洋證券此前指出,MRG003是樂普生物研發的EGFR靶向ADC,鼻咽癌適應症NDA已獲CDE的正式受理,並納入優先審評,有望在2025年底或者2026年初獲批,成為國內首款商業化的EGFR ADC。MRG003同步在美國開展臨牀試驗,並獲FDA授予BTD。另據天風證券,樂普生物多款ADC在臨牀階段,包括MRG004A、MRG006A、MRG007等。MRG004A(TF ADC) 用於治療胰腺癌獲得FDA授予FTD/ODD,正在開展Ib期的擴組,進行劑量優化。MRG006A(GPC3 ADC具有FIC潛力,正在積極進行I期探索,美國IND已獲批。MRG007,針對消化道癌的潛在同類最佳 ADC,已完成海外權益授出。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account